Insperity Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.55%.
Did NSP Beat Earnings? Q3 2025 Results
Insperity delivered a bruising third quarter, posting an adjusted loss of $0.20 per share against a consensus estimate of $0.22, missing by 190.09% as surging healthcare benefit costs overwhelmed modest top-line growth. Revenue rose 4.0% year-over-year to $1.62 billion, just shy of the $1.63 billion analysts had expected, with average paid worksite employees climbing 1% to 312,842. The core problem was an acute spike in inpatient, outpatient, pharmacy, and large-claim costs that drove gross profit down 15% to $195.00 million, widening the operating loss to $25.00 million from a slim $1.00 million gain a year ago. The brightest development of the quarter was a multi-year contract extension with UnitedHealthcare through 2028, which management said would meaningfully reduce costs and lower the large-claim pooling threshold to $500,000 beginning January 2026, substantially improving the forward outlook. Full-year 2025 adjusted EPS guidance of $0.84 to $1.47 reflects persistent near-term pressure, with Q4 expected to produce another adjusted loss, before the new UHC structure and the freshly launched HRScale offering with Workday can take effect.
- Revenue growth of 4% driven by 3% increase in revenue per WSEE on higher pricing and 1% increase in paid WSEEs
- Gross profit declined 15% due to higher-than-expected healthcare benefits costs including elevated inpatient, outpatient, pharmacy trends, and large claim frequency
- Operating expenses decreased 4% partly due to reduced Workday partnership spending ($11M vs $19M in Q3 2024)
- General and administrative expenses declined 15% year-over-year
“We are actively working to position Insperity for sustainable profitability at normal historical levels as we execute on our plan in response to unexpected, elevated healthcare cost trend. We are simultaneously taking assertive actions, including through the new contract with UnitedHealthcare, and will continue to focus on attracting and retaining the right clients at the right price and prudently managing expenses.”
Insperity CEO, on the earnings call
Forward Guidance & Outlook
Insperity updated its 2025 guidance: Full year 2025 average WSEEs paid of 310,200 to 310,700 (up 1.0% to 1.1% YoY); full year adjusted EPS of $0.84 to $1.47 (down 77% to 59% YoY); full year adjusted EBITDA of $119 million to $153 million (down 56% to 43% YoY). Q4 2025 guidance calls for average WSEEs paid of 313,000 to 315,000 (up 1.3% to 1.9% YoY); adjusted EPS of $(0.79) to $(0.16); and adjusted EBITDA of $(25) million to $9 million. The new UnitedHealthcare contract extending through 2028 is expected to provide significant cost savings and reduced risk starting January 1, 2026, with management expressing confidence that it substantially improves the 2026 financial outlook. HRScale rollout with Workday is underway and expected to serve as a catalyst for future growth.
NSP YoY Financials
Figures from SEC filings and company reports. Not investment advice.